Exploratory Study Using a New Head-only PET Scanner / ExploreNeuroLF

Launched by POSITRIGO AG · Mar 27, 2024

Keywords

ClinConnect Summary

This clinical trial, called ExploreNeuroLF, is studying a new type of brain imaging called the NeuroLF prototype, which is a special head-only PET scanner. This scanner aims to capture images of the brain using a small amount of a radioactive substance that patients will already have in their system from a regular PET scan they just completed. By using the leftover tracer, the trial hopes to see if the new scanner can provide valuable brain images without needing an extra dose of the radioactive tracer.

To participate in this study, you need to be between 18 and 80 years old and able to sit still for about 15 minutes. You should also be scheduled for a regular brain PET scan as part of your usual care. However, certain conditions may prevent you from joining, such as having metal implants in your head, being pregnant or breastfeeding, or having other health issues that make it hard to follow the study procedures. If you join, you can expect a straightforward process where you’ll have both the regular brain scan and the new NeuroLF scan to compare the results.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Capable of giving Informed Consent as documented by signature (Appendix Informed Consent Form).
• • Ability to sit still in the head-only PET scanner for 15 minutes.
• • Are scheduled to receive a regular brain PET scan as part of clinical routine.
• • Male and Female patients 18 years to 80 years of age.
• Exclusion Criteria:
• • Contraindications to PET examination,
• • Patient height smaller than 160 cm or taller than 200 cm,
• • Patient weight more than 120 kg,
• • Patient cannot sit upright for at least 15 minutes,
• • Metal implants in the head,
• • Pregnant or Breastfeeding women,
• • Known or suspected non-compliance, drug or alcohol abuse,
• • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
• • Participation in another study with investigational drug/device within the 30 days preceding and during the present study,
• • Previous enrolment into the current study,
• • Enrolment of the investigator, his/her family members, employees and other dependent persons.